Sign up today, get Edge free for 30 days.

Ad free · Full sentiment data · No credit card required

Exchange: OTC·Updated 09:35 AM EDT

About ATHJF

About

Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the following segments: ATL1102 and HMBD-002. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The HMBD-002 segment refers to a recombinant, humanised monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Percheron Therapeutics Ltd.?
What is the 52-week high for Percheron Therapeutics Ltd.?
What is the 52-week low for Percheron Therapeutics Ltd.?
What is Percheron Therapeutics Ltd. stock price today?
What was Percheron Therapeutics Ltd. stock price yesterday?
What is the PE ratio of Percheron Therapeutics Ltd.?
What is the Price-to-Book ratio of Percheron Therapeutics Ltd.?
What is the 50-day moving average of Percheron Therapeutics Ltd.?